0000950170-25-027982 Sample Contracts
LOAN AGREEMENT Dated as of November 1, 2024 among GERON CORPORATION (as Borrower and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral...Loan Agreement • February 27th, 2025 • Geron Corp • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of November 1, 2024 (the “Effective Date”) by and among GERON CORPORATION, a Delaware corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined).
EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2025 • Geron Corp • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made effective as of November 11, 2024 (the “Effective Date”), by and between Joseph Eid, M.D. (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY...Purchase and Sale Agreement • February 27th, 2025 • Geron Corp • Pharmaceutical preparations • New York
This REVENUE PARTICIPATION RIGHT purchase and sale AGREEMENT (this “Agreement”), dated as of November 1, 2024 (the “Effective Date”), is made and entered into by and between Royalty Pharma Development Funding, LLC, a Delaware limited liability company (the “Buyer”), and Geron Corporation, a Delaware corporation (the “Seller”).